Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment

ORLANDO, Fla., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Biostax Corp (OTC Pink: BTAX), a leading public company specializing in healthcare solutions, today announced a milestone in its transformative rebranding initiative. Both the State of Florida and FINRA have approved its name change from Immune Therapeutics, Inc. to Biostax and is now trading on OTC Pink Markets under the ticker symbol “BTAX”. This strategic shift signifies the company's planned pivot towards the international commercial application of substance abuse solutions and its commitment to innovative HIV treatment.

Biostax is looking to leverage its expertise and global reach to address the critical challenges of substance abuse internationally. By deploying evidence-based interventions and collaborating with international partners, the company aims to provide comprehensive, scalable solutions to individuals and communities affected by substance abuse. Through its commercial initiatives, Biostax seeks to make a significant impact by offering accessible and effective products and services designed to support recovery and improve the quality of life for those struggling with substance abuse.

Additionally, Biostax remains steadfast in its dedication to advancing HIV treatment. The company's research and development efforts focus on pioneering therapies that enhance the lives of individuals living with HIV. By combining Biostax naltrexone technology with Immgenuity, Inc.’s vaccine platform the company aims to position itself at the forefront of innovation in the field, aiming to improve health outcomes for those affected by HIV.

Commenting on the strategic direction, Biostax’s CEO, Noreen Griffin, stated, “Our rebranding marks a new chapter in our company’s journey. By entering the global substance abuse commercial markets and continuing our pioneering work in HIV treatment, we are positioning ourselves as leaders in addressing some of the world’s most pressing healthcare challenges. We are dedicated to making a meaningful difference in the lives of individuals and communities worldwide.”

Biostax is committed to transparency and will provide further updates and detailed information about its commercial partnerships in the substance abuse sector over the coming quarters. Additionally, the company will be launching an updated website in the coming months, offering a user-friendly platform for stakeholders, partners, and the public to access relevant information about its initiatives and progress.